Nemours Children'S Hospital, Delaware
United States
Nemours NCI Community Oncology Research Program (NCORP)
Nemours is an internationally recognized, multi-site pediatric healthcare system that is built upon a centralized, efficient and collaborative research infrastructure committed to improving the health of all children. In 2014, with over 25 years’ experience in clinical trials research, the four Nemours Center for Cancer and Blood Disorders (NCCBD) sites received funding as a NCI Community Oncology Research Program dedicated to children with cancer through participation in the Children’s Oncology Group (COG) Research Base trials. The Nemours Alfred I duPont Hospital for Children (NCCBD-Wilmington, DE), Nemours Children's Clinics (NCCBD-Jacksonville, Florida), Nemours Children's Hospital (NCCBD-Orlando, FL) and Sacred Heart, Pensacola, FL all had outstanding records of clinical trial participation and collaboration under the Nemours NCORP operational structure. In the current application, the Nemours NCORP will add a fifth site, Broward Heath (Ft. Lauderdale, Florida). The mission of the Nemours NCORP is to ensure that each child and young adolescent within our community-based catchment area has the opportunity to participate in national cancer control, cancer prevention, and cancer treatment trials as appropriate. The Nemours NCORP will continue to sustain systems supportive of cancer control, cancer prevention, care delivery, and treatment research, as well as to maintain robust quality management and improvement practices. Through Nemours’ already well-established network of healthcare institutions, community-based physician practices, and strong community ties, we will continue to extend access to research trials to children from all representative populations. Inclusive of all sites, the Nemours NCORP is consistently among the highest enrolling contributors to the Children’s Oncology Group Research Base studies, providing the opportunity to learn from all children with ultra-rare diseases.
Publications
- Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Dec 1;27(23):6314-6322. Epub 2021 Sep 27. PMID: 34580114
- Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 May 1;27(9):2435-2441. Epub 2021 Feb 10. PMID: 33568346
- Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Annals of surgery. 2020 Sep 1;272(3):481-486. PMID: 32740235
- Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature medicine. 2020 Oct;26(10):1564-1568. Epub 2020 Oct 5. PMID: 33020646
- Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical lung cancer. 2021 May;22(3):170-177. Epub 2020 Oct 14. PMID: 33221175
Clinical Trials
Study Name | Clinical Trial ID |
---|---|
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma | NCT00899990 |
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | NCT00736749 |
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors | NCT00082745 |
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | NCT00898079 |
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors | NCT00919750 |
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma | NCT00899275 |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | NCT00904241 |
Neuropsychological and Behavioral Testing in Younger Patients With Cancer | NCT00772200 |
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | NCT00897325 |
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma | NCT00919269 |
Study of Blood Samples From Newborns With Down Syndrome | NCT00959283 |
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | NCT01000753 |
Study of Kidney Tumors in Younger Patients | NCT00898365 |